{"disease":{"id":"xiap-deficiency","name":"xiap deficiency"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04641442","title":"Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 Mutations","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":17,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT03113760","title":"Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"AB2 Bio Ltd.","has_results":true},{"nct_id":"NCT03512314","title":"Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency As Open Label Extension","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":11,"lead_sponsor_name":"AB2 Bio Ltd.","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}